Canakinumab
| Evidence Level: L5 | Predicted Indications: 56 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Canakinumab |
| DrugBank ID | DB06168 |
| Brand Names (EU) | Ilaris |
| Evidence Level | L5 |
| Predicted Indications | 56 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: Muckle-Wells syndrome (MWS), Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), Severe forms of fami
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hepatic infarction | 99.86% | DL |
| 2 | hepatic veno-occlusive disease | 99.82% | DL |
| 3 | peliosis hepatis | 99.78% | DL |
| 4 | syndrome with combined immunodeficiency | 99.71% | DL |
| 5 | autosomal dominant familial periodic fever | 99.68% | DL |
| 6 | periodic fever-infantile enterocolitis-autoinflammatory syndrome | 99.57% | DL |
| 7 | autosomal recessive familial Mediterranean fever | 99.55% | DL |
| 8 | familial Mediterranean fever, autosomal dominant | 99.41% | DL |
| 9 | extracutaneous mastocytoma | 99.35% | DL |
| 10 | Blau syndrome | 99.34% | DL |
| 11 | monosomy X | 99.31% | DL |
| 12 | liver angiosarcoma | 99.30% | DL |
| 13 | aggressive systemic mastocytosis | 99.29% | DL |
| 14 | X-linked lymphoproliferative disease due to SH2D1A deficiency | 99.26% | DL |
| 15 | familial Mediterranean fever | 99.21% | DL |
| 16 | primary release disorder of platelets | 99.16% | DL |
| 17 | pseudo-von Willebrand disease | 99.13% | DL |
| 18 | hepatic veno-occlusive disease-immunodeficiency syndrome | 99.08% | DL |
| 19 | systemic mastocytosis | 99.05% | DL |
| 20 | chromhidrosis | 99.03% | DL |
Showing top 20 of 56 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.